Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment
Authors
Keywords
-
Journal
Nature Reviews Rheumatology
Volume 13, Issue 12, Pages 707-718
Publisher
Springer Nature
Online
2017-11-21
DOI
10.1038/nrrheum.2017.187
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance
- (2017) Claire Liefferinckx et al. INFLAMMATORY BOWEL DISEASES
- Transmembrane TNF-dependent uptake of anti-TNF antibodies
- (2017) Arun Deora et al. mAbs
- Validation of a Drug-Resistant Anti-Adalimumab Antibody Assay to Monitor Immunogenicity in the Presence of High Concentrations of Adalimumab
- (2016) Sumin Bian et al. AAPS Journal
- Validation of a sample pretreatment protocol to convert a drug-sensitive into a drug-tolerant anti-infliximab antibody immunoassay
- (2016) Thomas Van Stappen et al. Drug Testing and Analysis
- Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn’s disease: systematic reviews and economic modelling
- (2016) Karoline Freeman et al. HEALTH TECHNOLOGY ASSESSMENT
- Biology of anti-TNF agents in immune-mediated inflammatory diseases: therapeutic implications
- (2016) Roger A Levy et al. Immunotherapy
- Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis
- (2016) Young Ho Lee et al. RHEUMATOLOGY INTERNATIONAL
- Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL
- (2015) Bárbara P. Fafá et al. CLINICAL RHEUMATOLOGY
- Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima
- (2015) Shomron Ben-Horin et al. GUT
- Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern?
- (2015) Fabiola Atzeni et al. Immunotherapy
- Association of HLA-DRB1 Haplotypes With Rheumatoid Arthritis Severity, Mortality, and Treatment Response
- (2015) Sebastien Viatte et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers
- (2015) Thierry Lequerré et al. JOINT BONE SPINE
- Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: a Possible Explanation for a Lack of Clinical Response
- (2015) Rossella Talotta et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up
- (2015) Der-Yuan Chen et al. RHEUMATOLOGY
- Rheumatoid arthritis response to treatment across IgG1 allotype – anti-TNF incompatibility: a case-only study
- (2015) Ariana Montes et al. ARTHRITIS RESEARCH & THERAPY
- The 'Switch’ study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug
- (2015) Nuria C Navarro Coy et al. BMC MUSCULOSKELETAL DISORDERS
- Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis
- (2014) Der-Yuan Chen et al. ANNALS OF THE RHEUMATIC DISEASES
- The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region
- (2014) K A van Schie et al. ANNALS OF THE RHEUMATIC DISEASES
- Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs
- (2014) E H Vogelzang et al. ANNALS OF THE RHEUMATIC DISEASES
- Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase
- (2014) Michael H Schiff et al. ANNALS OF THE RHEUMATIC DISEASES
- Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice
- (2014) Eva L Kneepkens et al. ANNALS OF THE RHEUMATIC DISEASES
- Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up
- (2014) E L Kneepkens et al. ANNALS OF THE RHEUMATIC DISEASES
- Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register
- (2014) Katerina Chatzidionysiou et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
- (2014) Gerd-Rűdiger Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study
- (2014) P Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Ten-Year Drug Survival of Anti-TNF Agents in the Treatment of Inflammatory Arthritides
- (2014) Martina Biggioggero et al. DRUG DEVELOPMENT RESEARCH
- Hypersensitivity Reactions to Biologic Agents
- (2014) Alessandra Vultaggio et al. IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
- Antibodies Against Infliximab Are Associated with De Novo Development of Antibodies to Adalimumab and Therapeutic Failure in Infliximab-to-Adalimumab Switchers with IBD
- (2014) Madeline Therese Frederiksen et al. INFLAMMATORY BOWEL DISEASES
- Drug Survival Rates of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
- (2014) Ji-Hyoun Kang et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Genetic and epigenetic predictors of responsiveness to treatment in RA
- (2014) Darren Plant et al. Nature Reviews Rheumatology
- Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies
- (2014) E. G. Favalli et al. RHEUMATOLOGY
- Key findings towards optimising adalimumab treatment: the concentration–effect curve
- (2013) Mieke F Pouw et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
- (2013) Dae Hyun Yoo et al. ANNALS OF THE RHEUMATIC DISEASES
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
- (2013) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
- (2013) M. Jani et al. RHEUMATOLOGY
- Immunogenicity/Hypersensitivity of Biologics
- (2013) Michael W. Leach et al. TOXICOLOGIC PATHOLOGY
- Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis
- (2013) Jing Cui et al. PLoS Genetics
- Immunogenicity of Monoclonal Antibodies Against Tumor Necrosis Factor Used in Chronic Immune-Mediated Inflammatory Conditions
- (2013) Jose Ramon Maneiro et al. JAMA Internal Medicine
- Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
- (2012) Sanne A A van Dartel et al. ANNALS OF THE RHEUMATIC DISEASES
- Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner
- (2012) Charlotte L Krieckaert et al. ANNALS OF THE RHEUMATIC DISEASES
- Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients
- (2012) Sophie Martin Du Pan et al. ANNALS OF THE RHEUMATIC DISEASES
- Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation
- (2012) Pauline A van Schouwenburg et al. ANNALS OF THE RHEUMATIC DISEASES
- The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis
- (2012) Sandra Garcês et al. ANNALS OF THE RHEUMATIC DISEASES
- The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers
- (2012) Martina Fabris et al. ARTHRITIS AND RHEUMATISM
- Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension
- (2012) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Immunogenicity of biological therapeutics
- (2012) Charlotte Krieckaert et al. CURRENT OPINION IN RHEUMATOLOGY
- Longterm Retention of Tumor Necrosis Factor- Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors
- (2012) F. IANNONE et al. JOURNAL OF RHEUMATOLOGY
- Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment
- (2012) P. Emery RHEUMATOLOGY
- Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial
- (2011) J. M. Kremer et al. ANNALS OF THE RHEUMATIC DISEASES
- Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management
- (2011) Alessandra Vultaggio et al. Current Opinion in Allergy and Clinical Immunology
- Differential effect of drug interference in immunogenicity assays
- (2011) Margreet H. Hart et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
- (2011) Emilie Ducourau et al. ARTHRITIS RESEARCH & THERAPY
- Body mass index and clinical response to infliximab in rheumatoid arthritis
- (2010) Ruth Klaasen et al. ARTHRITIS AND RHEUMATISM
- Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci
- (2010) Darren Plant et al. ARTHRITIS AND RHEUMATISM
- Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model
- (2010) A. Joseph et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Ron J. Keizer et al. CLINICAL PHARMACOKINETICS
- Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions
- (2009) A. Vultaggio et al. ALLERGY
- Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation
- (2009) M K de Vries et al. ANNALS OF THE RHEUMATIC DISEASES
- Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
- (2009) A Finckh et al. ANNALS OF THE RHEUMATIC DISEASES
- Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry
- (2009) Merete Lund Hetland et al. ARTHRITIS AND RHEUMATISM
- Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor
- (2009) M Margarida Souto-Carneiro et al. ARTHRITIS RESEARCH & THERAPY
- Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis
- (2008) C Potter et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
- (2008) R Fleischmann et al. ANNALS OF THE RHEUMATIC DISEASES
- Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
- (2008) T R D J Radstake et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis
- (2008) M K de Vries et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunogenicity of anti-tumor necrosis factor antibodies—toward improved methods of anti-antibody measurement
- (2008) Lucien Aarden et al. CURRENT OPINION IN IMMUNOLOGY
- Rheumatoid Arthritis
- (2008) Joseph R Lutt et al. DRUGS
- Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products
- (2008) Gopi Shankar et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Therapeutic advances in rheumatology with the use of recombinant proteins
- (2008) Achim Rothe et al. Nature clinical practice. Rheumatology
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
- (2007) Daniel Tracey et al. PHARMACOLOGY & THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now